# Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

> **NCT05891561** · PHASE2 · RECRUITING · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 120 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT05891561
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05891561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05891561, "Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05891561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*